FDA Mandates Boxed Warning on Symptomatic Hypophosphatemia for Ferric Carboxymaltose Injection
Based on an agency safety communication issued by the US Food and Drug Administration.
The US Food and Drug Administration (FDA) has mandated the addition of a boxed warning to the prescribing information for ferric carboxymaltose injection (Injectafer; Daiichi Sankyo/American Regent) and its generic equivalents. The boxed warning addresses the documented risk of developing symptomatic hypophosphatemia following single or repeated infusions and outlines serum phosphate monitoring requirements for at-risk populations.
Approved Indications and Clinical Spectrum
Ferric carboxymaltose is an intravenous iron replacement complex indicated across pediatric and adult patient groups presenting with iron deficiency where oral iron formulations are either ineffective or clinically inappropriate.
Table 1. Current FDA-Approved Indications for Ferric Carboxymaltose
| Target Patient Population | Clinical Criteria / Diagnostic Setting | Intended Therapeutic Goal |
| Pediatric Patients ($\ge$1 Year) & Adults | Documented iron deficiency anemia with intolerance or unsatisfactory response to oral iron | Systemic iron repletion and anemia correction |
| Adults With Chronic Kidney Disease (CKD) | Non-dialysis-dependent CKD with iron deficiency | Iron repletion without requirement for hemodialysis access |
| Adults With Chronic Heart Failure | New York Heart Association (NYHA) functional class II or III with iron deficiency | Improvement in functional exercise capacity |
Safety Signal Assessment and Underutilization of Surveillance
The regulatory mandate follows an extensive evaluation of real-world surveillance data, including postmarketing safety reports from the FDA Adverse Event Reporting System (FAERS) and published medical literature. Clinicians reported numerous cases of symptomatic hypophosphatemia after single and repeated infusions despite prior drug label modifications in 2020 and 2023 intended to heighten clinician awareness.
Data extracted from the FDAโs Sentinel System demonstrated that laboratory surveillance has been substantially underutilized in routine clinical practice, with baseline or follow-up serum phosphate laboratory evaluations occurring in fewer than 20% of all ferric carboxymaltose administration episodes.
Table 2. Clinical Spectrum of Hypophosphatemia and Regulatory Directives
| Clinical Category | Documented Manifestations and Regulatory Directives |
| Acute / Symptomatic Presentations | * Muscle weakness or muscle pain * Severe fatigue * Tremors * Acute confusion * Seizures * Cardiac arrhythmias |
| Severe Downstream Complications | * Acute hospitalization * Prolonged requirement for oral or intravenous phosphate repletion * Osteomalacia * Bone fractures (fragility/insufficiency fractures) |
| High-Risk Surveillance Cohorts | * Patients with pre-existing risk factors for electrolyte or phosphate wasting * Patients receiving repeat courses of therapy within 3 months of a prior administration |
| Laboratory Testing Underutilization | Documented serum phosphate testing performed in <20% of treatment episodes |
| Prescribing & Discontinuation Directives | * Mandatory pre-treatment patient counseling regarding hypophosphatemia symptoms * Serial monitoring of serum phosphate levels in at-risk cohorts * Permanent discontinuation recommended in patients with persistent or severe chronic hypophosphatemia |
Practice Recommendations for Clinicians
The updated labeling directives state that healthcare professionals must actively counsel patients on the signs and symptoms of hypophosphatemia prior to initiating ferric carboxymaltose therapy. For patients identified as biologically at-risk or those requiring repeated administration cycles within a 3-month window from their preceding infusion, systematic biochemical monitoring of serum phosphate levels is advised. In cases where patients develop persistent hypophosphatemia or severe chronic hypophosphatemia, clinicians should permanently discontinue the drug and evaluate alternative therapies. Generic manufacturers of ferric carboxymaltose injection are required to update their respective product labels with identical boxed warnings.
